相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021
Ginny Beakes-Read et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2022)
An urgent call to raise the bar in oncology
John-John B. Schnog et al.
BRITISH JOURNAL OF CANCER (2021)
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective obser-vational study
Bishal Gyawali et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval
Kerrington Powell et al.
JAMA ONCOLOGY (2021)
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why
Mwango Kashoki et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
Tania Teixeira et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Project Orbis: Global Collaborative Review Program
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2020)
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States
Maximilian Salcher-Konrad et al.
MILBANK QUARTERLY (2020)
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
Thomas J. Hwang et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA
Simon Dalla Torre Di Sanguinetto et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2019)
To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016
Thomas Christian Kuhler et al.
BMJ OPEN (2019)
A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs
Minette-Joelle Zeukeng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency
Petra Dorr et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2016)
How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views
G. Tafuri et al.
ANNALS OF ONCOLOGY (2014)
Comparison of Drug Approvals in Europe Versus the United States: An Analysis of Discrepancies Between Drug Products Reviewed by EMA and FDA
Robert W. Makuch et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2014)
Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice
Francesco Trotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
分享论文
